Skip to main content

Table 2 Changes in lipid variables over four weeks in patients with and without T2D

From: The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period

 

non-T2D

Mean changes

T2D

Mean changes

p*

LDL-C (mmol/L)

-0.25 [-0.29, -0.21]

-0.18 [-0.20, -0.17]

0.0004

HDL-C (mmol/L)

-0.03 [-0.04, -0.02]

-0.02 [-0.02, -0.01]

0.0014

VLDL-C (mmol/L)

-0.09 [-0.11, -0.08]

-0.08 [-0.09, -0.07]

0.1564

TC (mmol/L)

-0.37 [-0.41, -0.33]

-0.29 [-0.31, -0.28]

0.0009

Triglycerides (mmol/L)

-0.22 [-0.27, -0.18]

-0.25 [-0.27, -0.22]

0.3231

BMI (kg/m2)

-0.81 [-0.84, -0.78]

-0.73 [-0.75, -0.72]

0.3887

  1. In all instances, within-group changes from baseline were statistically significant (P < 0.0001)
  2. Data presented as means and 95% Confidence intervals.
  3. *P-values for difference in mean changes.
  4. 13 patients with unknown risk category were excluded.